- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05673525
A Clinical Trial of the Transcatheter Aortic Valve Implantation System With a Prospective, Multi-Center, One-Arm Approach to Evaluate the Efficacy and Safety in the Treatment of Patients With Severe Aortic Stenosis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This trial consists of two parts. Part I, the Feasibility trial: 10-12 patients with severe aortic stenosis who meet inclusion/exclusion criteria and are at high surgical risk or not suitable for conventional surgical valve replacement are selected at no more than 5 centers for implantation of an aortic valve by transcatheter aortic valve replacement (KOKA-VALVE) to achieve treatment of aortic valve disease in subjects. All-cause mortality at 30 days after implantation is used as the primary endpoint, and the immediate postoperative device success and surgical success, major cardiovascular adverse events at 1 year after implantation, transvalvular pressure difference at 30 days and 12 months after implantation, degree of orifice regurgitation, degree of perivalvular leakage, improvement in NYHA cardiac function, and improvement in quality of survival are used as the secondary endpoints to supplementarily evaluate the safety and feasibility of this product. It also provides experience and reference for further Part II confirmatory trials and applications to ensure safe conduct of confirmatory trials. Subjects in the feasibility trial may continue to be followed up at 6 months after implantation and 12 months after implantation after completion of the one-month postoperative follow-up. All subjects will also continue to be followed up by telephone at 24, 36, 48, and 60 months after implantation.
Part II, the Confirmatory Trial: Designed with a prospective, multi-center, one-arm approach. 131 patients with severe aortic stenosis who meet inclusion/non-exclusion criteria and are at high surgical risk or unsuitable for conventional surgical valve replacement are implanted with an aortic valve by transcatheter aortic valve replacement (KOKA-VALVE) to achieve treatment of aortic valve disease in subjects. All-cause mortality at 30 days after implantation is used as the primary endpoint, and the immediate postoperative device success and surgical success, major cardiovascular adverse events at 1 year after implantation, transvalvular pressure difference at 30 days and 12 months after implantation, degree of orifice regurgitation, degree of perivalvular leakage, improvement in NYHA cardiac function, and improvement in quality of survival are used as the secondary endpoints to supplementarily evaluate the safety and feasibility of this product.
All patients will be followed up before discharge, 30 days, 6 months, and 12 months after implantation after product implantation. All subjects will be followed up by telephone at 24 months, 36 months, 48 months and 60 months after implantation.
The study will be conducted at multiple clinical trial sites nationwide, and 131 subjects will be enrolled in the confirmatory trial. The enrollment and treatment status of the subjects will be recorded during the study, and the subjects will be followed up before discharge, 6 months after implantation, and 12 months after implantation, and the data will be compiled for registration and declaration.
All subjects will be followed up by telephone at 24 months, 36 months, 48 months, and 60 months after implantation.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Chunrui Xiang
- Phone Number: +86 17601425727
- Email: crxiang@kokalife.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China
- Structral Heart Disease Center, Fuwai Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Contraindication to surgery, or high risk for surgery (STS ≥ 8%) as assessed by the heart team; or other circumstances that make surgical valve replacement inappropriate.
- Age ≥65 years.
- Patients with symptomatic severe aortic stenosis (mean aortic transvalvular gradient by echocardiography ≥40 mmHg (1 mmHg=0.133 kPa), or transaortic flow velocity ≥4.0 m/s, or aortic valve orifice area <0.8 cm2, or effective aortic orifice area index <0.5 cm2 /m2).
- The subjects have been informed of the nature of this study, understand the purpose of the clinical trial, and voluntarily participate in and sign the informed consent form.
Exclusion Criteria:
- Life expectancy less than 1 year after implantation of the prosthetic valve.
- Patients had an acute heart attack within 1 month, or had a coronary stent or a pacing device implantation within 1 month, or had any therapeutic cardiac surgery within 1 month.
- Patients with aortic root anatomy and lesion that are not suitable for prosthetic valve implantation.
- Combined with severe insufficiency or stenosis of other valves and requiring surgical treatment.
- Hematologic cachexia, including leukopenia (WBC <3×10^9 /L), acute anemia (HB <90 g/L), thrombocytopenia (PLT <50 × 10^9 /L), bleeding constitution, and coagulation disorders.
- Untreated coronary artery disease requiring hematologic reconstruction.
- Hypertrophic obstructive cardiomyopathy.
- Severe left ventricular dysfunction with left ventricular ejection fraction (LVEF) <20%.
- Severe right ventricular insufficiency.
- The existent of intracardiac masses, thrombi or superfluous organisms by echocardiography.
- Patients who cannot tolerate anticoagulation or antiplatelet therapy.
- Patients had cerebrovascular event (CVA), including ischemic stroke and hemorrhagic stroke within 3 months.
- Decompensation of renal insufficiency.
- Active infective endocarditis or other active infection.
- Untreated conduction system disease requiring pacemaker implantation.
- Currently participating in an investigational drug or another device study that has not completed its primary endpoints or would clinically interfere with the endpoint of this study.
- Other circumstances that are assessed by the investigator to be unsuitable for interventional aortic valve therapy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment Group
|
Transcatheter Aortic Valve Implantation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
All-cause mortality
Time Frame: 12 months postoperatively
|
Cumulative all-cause mortality at 12 months postoperatively
|
12 months postoperatively
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Transvalvular Gradient
Time Frame: 30 days and 12 months postoperatively
|
Transvalvular Gradients at 30 days and 12 months postoperatively
|
30 days and 12 months postoperatively
|
Aortic Regurgitation Degree
Time Frame: 30 days and 12 months postoperatively
|
Aortic Regurgitation Degree at 30 days and 12 months postoperatively
|
30 days and 12 months postoperatively
|
Perivalvular Leakage
Time Frame: 30 days and 12 months postoperatively
|
Perivalvular Leakage at 30 days and 12 months postoperatively
|
30 days and 12 months postoperatively
|
Cardiac Function
Time Frame: 30 days and 12 months postoperatively
|
The rate of New York Heart Association (NYHA) Function Class at 30 days and 12 months postoperatively
|
30 days and 12 months postoperatively
|
Quality of Survival
Time Frame: 30 days and 12 months postoperatively
|
The score of EQ-5D at 30 days and 12 months postoperatively
|
30 days and 12 months postoperatively
|
Collaborators and Investigators
Investigators
- Principal Investigator: Xiangbin Pan, Fuwai Hospital
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- KOKA-2022-03
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aortic Stenosis
-
Hospices Civils de LyonRecruiting
-
Abbott Medical DevicesActive, not recruitingSevere Aortic Stenosis | Symptomatic Degenerative Aortic StenosisSpain, Italy, United Kingdom, Germany, Switzerland, Czechia, Australia, Belgium, Poland
-
Edwards LifesciencesActive, not recruitingAortic Stenosis | Aortic Regurgitation | Symptomatic Aortic StenosisChina
-
Anteris Technologies Ltd.Active, not recruitingAortic Valve Calcification | Severe Aortic Valve Stenosis | Symptomatic Aortic StenosisGeorgia
-
Anteris Technologies Ltd.Active, not recruitingAortic Stenosis | Aortic Valve Calcification | Severe Aortic Valve Stenosis | Symptomatic Aortic StenosisUnited States
-
Edwards LifesciencesCompletedAortic Stenosis | Aortic Regurgitation | Symptomatic Aortic StenosisChina
-
Ningbo Jenscare Biotechnology Co., Ltd.UnknownAortic Regurgitation | Severe Aortic Stenosis
-
Genesis Medtech CorporationRecruitingDiseases of Aortic Valve | Aortic Stenosis DiseaseChina
-
Saint Petersburg State University, RussiaNot yet recruitingIschemic Heart Disease | Mitral Insufficiency | Aortic Stenosis, Severe | Mitral Stenosis | Aortic Insufficiency | Ascending Aortic Aneurysm | Mitral Stenosis With Insufficiency | Tricuspid InsufficiencyRussian Federation
-
Pan XiangbinRecruiting
Clinical Trials on Transcatheter Aortic Valve Implantation (KOKA-VALVE)
-
University of PadovaFondazione GISE OnlusRecruiting
-
Clinique PasteurUnknownBicuspid Aortic ValveFrance
-
Didier TCHETCHEAbbottNot yet recruitingBicuspid Aortic ValveFrance
-
Xijing HospitalRecruitingAortic Valve RegurgitationChina
-
Xijing HospitalRecruiting
-
Xijing HospitalRecruitingAortic Valve Disease MixedChina
-
IRCCS Policlinico S. DonatoRecruiting
-
Medical University of WarsawRecruitingAortic Valve Stenosis | Ventricular Outflow Obstruction, LeftPoland
-
Segeberger Kliniken GmbHCompleted
-
Edwards LifesciencesCompletedSevere Aortic StenosisSpain, Italy, Canada, Belgium, Greece, Germany, Austria, United Kingdom, Finland, Denmark, France, Switzerland, Israel, Poland, South Africa, Czechia, Netherlands, Norway